文献速递淋巴瘤

AVD 可作为老年经典型霍奇金淋巴瘤一线化疗骨架

AVD is an effective chemotherapy backbone in first-line treatment of older patients with classical Hodgkin lymphoma.
PubMed 文献 · Blood Adv · 2026-01-01

研究汇总瑞典、丹麦、挪威 2000 至 2021 年诊断的 1569 例≥60 岁经典型霍奇金淋巴瘤患者,比较 ABVD、AVD、CHOP 等一线方案。多变量分析显示,AVD 的总生存优于 ABVD,无进展生存亦显著优于 ABVD,CHOP 的无进展生存与 ABVD 相当。作者认为 AVD 是老年患者更优的化疗选择,可作为新药联合的骨架。

要点

  • AVD 的总生存优于 ABVD,无进展生存亦显著优于 ABVD。
  • CHOP 的无进展生存与 ABVD 相当,但总生存呈劣于 ABVD 的趋势。
  • AVD 省略博来霉素,已知可降低治疗相关毒性。

核心结论

  • 在≥60 岁经典型霍奇金淋巴瘤患者中,AVD 的总生存和无进展生存至少不劣于 ABVD,且常优于 CHOP。
  • 基于上述结果,AVD 是老年经典型霍奇金淋巴瘤更优的化疗选择,应被视为新药联合治疗的骨架。

研究设计与样本

  • 研究为北欧三国(瑞典、丹麦、挪威)2000 至 2021 年诊断患者的队列数据汇总分析。
  • 共纳入 1569 例患者:瑞典 704 例(45%)、丹麦 671 例(43%)、挪威 194 例(12%)。

主要发现

  • 总生存多变量分析中,AVD 较 ABVD 与生存改善相关,CHOP 或其他方案呈生存劣于 ABVD 的趋势。
  • 无进展生存多变量分析中,AVD 相对 ABVD 显著改善结局,CHOP 组结局与 ABVD 相当。
  • 接受其他方案的患者结局倾向于更差。

临床怎么用

  • 对≥60 岁经典型霍奇金淋巴瘤患者,可优先考虑以 AVD 作为一线化疗骨架。
  • AVD 省略博来霉素,已知较 ABVD 降低治疗相关毒性,适合老年患者。
  • AVD 可作为与新型药物联合治疗的骨架方案。

局限性

  • 研究为回顾性队列数据汇总,非随机对照试验,方案选择可能存在混杂。
  • 原文未报告各方案的剂量、疗程及具体毒性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

No universal gold standard chemotherapy exists for the treatment of older (≥60 years) patients with classical Hodgkin lymphoma (cHL). To evaluate the current curative treatment strategies used in the Nordic countries, we collected data from patients diagnosed in Sweden, Denmark and Norway during the years 2000 to 2021. We included 1569 patients: 704 (45%) Swedish, 671 (43%) Danish, and 194 (12%) Norwegian. Of these, 671 (43%) received doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD), 123 (8%) received doxorubicin, vinblastine, and dacarbazine (AVD), 465 (31%) received cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), and 212 (13%) received other chemotherapy (single agent or combination). Eighty-two (5%) patients lacked information on first-line regimen. In multivariable analyses of overall survival (OS), treatment with AVD was associated with improved survival compared to ABVD, whereas there was a trend toward inferior survival among patients receiving CHOP or other regimens. For progression-free survival (PFS), multivariable analysis likewise demonstrated significantly improved outcome with AVD relative to ABVD, whereas outcomes for the CHOP group were comparable to ABVD. Outcome for patients receiving other regimens tended to be poorer. Collectively, outcome for AVD with respect to both OS and PFS was at least equal to ABVD and often superior to CHOP. By omitting bleomycin, treatment-related toxicity is known to be reduced in AVD compared to ABVD. Based on our findings, AVD is a preferable chemotherapy option in older patients with cHL and should rightly be considered as backbone in treatment with novel drugs.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Övergaard N, Lia K, Collin J, et al. AVD is an effective chemotherapy backbone in first-line treatment of older patients with classical Hodgkin lymphoma. Blood Adv. 2026. PMID: 41921203. doi:10.1182/bloodadvances.2025018954

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。